OSA's Digital Library

Biomedical Optics Express

Biomedical Optics Express

  • Editor: Joseph A. Izatt
  • Vol. 2, Iss. 6 — Jun. 1, 2011
  • pp: 1514–1523

Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue

R. J. Langsner, L. P. Middleton, J. Sun, F. Meric-Bernstam, K. K. Hunt, R. A. Drezek, and T. K. Yu  »View Author Affiliations


Biomedical Optics Express, Vol. 2, Issue 6, pp. 1514-1523 (2011)
http://dx.doi.org/10.1364/BOE.2.001514


View Full Text Article

Enhanced HTML    Acrobat PDF (1005 KB)





Browse Journals / Lookup Meetings

Browse by Journal and Year


   


Lookup Conference Papers

Close Browse Journals / Lookup Meetings

Article Tools

Share
Citations

Abstract

Rapid in situ determination of surgical resection margins during breast cancer surgery would reduce patient time under anesthesia. We present preliminary data supporting the use of a fluorescent glucose analog (2-NBDG) as an optical contrast agent to differentiate freshly excised breast tissue containing cancerous cells from normal breast tissue. Multi-spectral images of 14 breast cancer specimens acquired before and after incubation with 2-NBDG demonstrated increased fluorescent signal in all of the malignant tissue due to increased 2-NBDG consumption. We demonstrate that 2-NBDG has potential as an optical contrast agent to differentiate cancerous from non-cancerous tissue.

© 2011 OSA

OCIS Codes
(170.1610) Medical optics and biotechnology : Clinical applications
(170.3880) Medical optics and biotechnology : Medical and biological imaging

ToC Category:
Optics in Cancer Research

History
Original Manuscript: March 30, 2011
Revised Manuscript: May 2, 2011
Manuscript Accepted: May 10, 2011
Published: May 11, 2011

Citation
R. J. Langsner, L. P. Middleton, J. Sun, F. Meric-Bernstam, K. K. Hunt, R. A. Drezek, and T. K. Yu, "Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue," Biomed. Opt. Express 2, 1514-1523 (2011)
http://www.opticsinfobase.org/boe/abstract.cfm?URI=boe-2-6-1514


Sort:  Author  |  Year  |  Journal  |  Reset  

References

  1. N. Q. Mirza, G. Vlastos, F. Meric, T. A. Buchholz, N. Esnaola, S. E. Singletary, H. M. Kuerer, L. A. Newman, F. C. Ames, M. I. Ross, B. W. Feig, R. E. Pollock, M. McNeese, E. Strom, and K. K. Hunt, “Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy,” Ann. Surg. Oncol. 9(3), 256–265 (2002). [CrossRef] [PubMed]
  2. A. Luini, J. Rososchansky, G. Gatti, S. Zurrida, P. Caldarella, G. Viale, G. Rosali dos Santos, and A. Frasson, “The surgical margin status after breast-conserving surgery: discussion of an open issue,” Breast Cancer Res. Treat. 113(2), 397–402 (2009). [CrossRef] [PubMed]
  3. L. R. Bickford, G. Agollah, R. Drezek, and T. K. Yu, “Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy,” Breast Cancer Res. Treat. 120(3), 547–555 (2010). [CrossRef] [PubMed]
  4. L. P. Adler, P. F. Faulhaber, K. C. Schnur, N. L. Al-Kasi, and R. R. Shenk, “Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET,” Radiology 203(2), 323–327 (1997). [PubMed]
  5. M. Schelling, N. Avril, J. Nährig, W. Kuhn, W. Römer, D. Sattler, M. Werner, J. Dose, F. Jänicke, H. Graeff, and M. Schwaiger, “Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer,” J. Clin. Oncol. 18(8), 1689–1695 (2000). [PubMed]
  6. R. L. Wahl, R. L. Cody, G. D. Hutchins, and E. E. Mudgett, “Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose,” Radiology 179(3), 765–770 (1991). [PubMed]
  7. O. Warburg, F. Wind, and E. Negelein, “The metabolism of tumors in the body,” J. Gen. Physiol. 8(6), 519–530 (1927). [CrossRef] [PubMed]
  8. L. P. Adler, J. P. Crowe, N. K. al-Kaisi, and J. L. Sunshine, “Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET,” Radiology 187(3), 743–750 (1993). [PubMed]
  9. R. S. Brown, J. Y. Leung, P. V. Kison, K. R. Zasadny, A. Flint, and R. L. Wahl, “Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer,” J. Nucl. Med. 40(4), 556–565 (1999). [PubMed]
  10. R. S. Brown and R. L. Wahl, “Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study,” Cancer 72(10), 2979–2985 (1993). [CrossRef] [PubMed]
  11. G. Weber and A. Cantero, “Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues,” Cancer Res. 15(2), 105–108 (1955). [PubMed]
  12. K. Yu, S. J. Schomisch, V. Chandramouli, and Z. Lee, “Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma,” Comp. Biochem. Physiol. Part Toxicol. Pharmacol. 143(2), 225–231 (2006). [CrossRef]
  13. K. Yamada, M. Nakata, N. Horimoto, M. Saito, H. Matsuoka, and N. Inagaki, “Measurement of glucose uptake and intracellular calcium concentration in single, living pancreatic beta-cells,” J. Biol. Chem. 275(29), 22278–22283 (2000). [CrossRef] [PubMed]
  14. R. G. O’Neil, L. Wu, and N. Mullani, “Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells,” Mol. Imaging Biol. 7(6), 388–392 (2005). [CrossRef] [PubMed]
  15. N. Nitin, A. L. Carlson, T. Muldoon, A. K. El-Naggar, A. Gillenwater, and R. Richards-Kortum, “Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose,” Int. J. Cancer 124(11), 2634–2642 (2009). [CrossRef] [PubMed]
  16. A. Fourquet, F. Campana, B. Zafrani, V. Mosseri, P. Vielh, J. C. Durand, and J. R. Vilcoq, “Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up,” Int. J. Radiat. Oncol. Biol. Phys. 17(4), 719–725 (1989). [CrossRef] [PubMed]
  17. M. C. Smitt, K. Nowels, R. W. Carlson, and S. S. Jeffrey, “Predictors of reexcision findings and recurrence after breast conservation,” Int. J. Radiat. Oncol. Biol. Phys. 57(4), 979–985 (2003). [CrossRef] [PubMed]
  18. S. C. Renton, J. C. Gazet, H. T. Ford, C. Corbishley, and R. Sutcliffe, “The importance of the resection margin in conservative surgery for breast cancer,” Eur. J. Surg. Oncol. 22(1), 17–22 (1996). [CrossRef] [PubMed]
  19. C. A. Perez, “Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities,” Cancer J. 9(6), 442–453 (2003). [CrossRef] [PubMed]
  20. M. E. Peterson, D. J. Schultz, C. Reynolds, and L. J. Solin, “Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience,” Int. J. Radiat. Oncol. Biol. Phys. 43(5), 1029–1035 (1999). [CrossRef] [PubMed]
  21. R. Heimann, C. Powers, H. J. Halpern, A. G. Michel, C. A. Ewing, B. Wyman, W. Recant, and R. R. Weichselbaum, “Breast preservation in stage I and II carcinoma of the breast. the University of Chicago experience,” Cancer 78(8), 1722–1730 (1996). [CrossRef] [PubMed]
  22. R. Bos, J. J. M. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff, “Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography,” J. Clin. Oncol. 20(2), 379–387 (2002). [CrossRef] [PubMed]
  23. N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Jänicke, W. Nathrath, and M. Schwaiger, “Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis,” J. Nucl. Med. 42(1), 9–16 (2001). [PubMed]
  24. N. Y. Tse, C. K. Hoh, R. A. Hawkins, M. J. Zinner, M. Dahlbom, Y. Choi, J. Maddahi, F. C. Brunicardi, M. E. Phelps, and J. A. Glaspy, “The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease,” Ann. Surg. 216(1), 27–34 (1992). [CrossRef] [PubMed]
  25. R. Bos, J. J. M. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff, “Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography,” J. Clin. Oncol. 20(2), 379–387 (2002). [CrossRef] [PubMed]
  26. A. M. Byrne, A. D. K. Hill, S. J. Skehan, E. W. McDermott, and N. J. O’Higgins, “Positron emission tomography in the staging and management of breast cancer,” Br. J. Surg. 91(11), 1398–1409 (2004). [CrossRef] [PubMed]
  27. O. E. Nieweg, E. E. Kim, W. H. Wong, W. F. Broussard, S. E. Singletary, G. N. Hortobagyi, and R. S. Tilbury, “Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer,” Cancer 71(12), 3920–3925 (1993). [CrossRef] [PubMed]
  28. L. Arnould, M. Gelly, F. Penault-Llorca, L. Benoit, F. Bonnetain, C. Migeon, V. Cabaret, V. Fermeaux, P. Bertheau, J. Garnier, J. F. Jeannin, and B. Coudert, “Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?” Br. J. Cancer 94(2), 259–267 (2006). [CrossRef] [PubMed]
  29. S. F. Dent, S. Verma, K. I. Pritchard, J. Latreille, D. Rayson, M. Clemons, J. R. Mackey, L. Provencher, S. Verma, J. Lemieux, S. Chia, and B. Wang, “The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer,” Curr. Oncol. 16(4), 25–35 (2009). [CrossRef] [PubMed]

Cited By

Alert me when this paper is cited

OSA is able to provide readers links to articles that cite this paper by participating in CrossRef's Cited-By Linking service. CrossRef includes content from more than 3000 publishers and societies. In addition to listing OSA journal articles that cite this paper, citing articles from other participating publishers will also be listed.

Figures

Fig. 1 Fig. 2 Fig. 3
 
Fig. 4
 

« Previous Article  |  Next Article »

OSA is a member of CrossRef.

CrossCheck Deposited